John Trizzino - Dec 14, 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, CCO and CBO
Signature
/s/ Mark Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Dec 14, 2023
Transactions value $
-$4,398
Form type
4
Date filed
12/18/2023, 05:12 PM
Previous filing
Aug 22, 2023
Next filing
Mar 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +1.6K +16.28% 11.4K Dec 14, 2023 Direct F1
transaction NVAX Common Stock Tax liability -$4.4K -773 -6.76% $5.69 10.7K Dec 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -1.6K -100% $0.00* 0 Dec 14, 2023 Common Stock 1.6K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units ("RSU"s) subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.
F2 The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
F3 Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.